Copyright
©2014 Baishideng Publishing Group Co.
World J Gastroenterol. Mar 7, 2014; 20(9): 2224-2236
Published online Mar 7, 2014. doi: 10.3748/wjg.v20.i9.2224
Published online Mar 7, 2014. doi: 10.3748/wjg.v20.i9.2224
Table 3 Clinical studies of second-line cytotoxic combination regimens
Ref. | Regimen | Sample size | RR1 | PFS/TTP (mo) | Med OS (mo) | 1 yr survival |
Platinum based regimens | ||||||
Tsavaris et al[29], 2005 | FOLFOX | 30 | 23% | 5.1 | 5.8 | NR |
Mitry et al[84], 2006 | FOLFOX | 18 | 0% | 0.9 | 1.3 | NR |
Gebbia et al[85], 2007 | FOLFOX | 42 | 14% | 4 | 6.7 | NR |
Novarino et al[86], 2009 | FOLFOX | 23 | 0% | 2.7 | 4.0 | NR |
Yoo et al[30], 2009 | FOLFOX | 30 | 6.7% | 1.4 | 3.5 | NR |
Chung et al[31], 2013 | FOLFOX | 44 | 11% | 2.3 | 7.3 | NR |
Berk et al[35], 2012 | FOLFOX | 46 | 17% | 3.7 | 5.8 | NR |
Sancho et al[32], 2008 | CapOx2 | 18 | 5.6% | 3.9 | 5.8 | NR |
Xiong et al[33], 2008 | CapOx | 41 | 2.4% | 2.3 | 5.4 | 21% |
Gasent-Blesa et al[34], 2009 | CapOx | 15 | 6.7% | NR | 5.3 | NR |
Berk et al[35], 2012 | CapOx | 39 | 18% | 3.7 | 4.9 | NR |
Pelzer et al[87], 2009 | OFF | 37 | 5.4% | 2.8 | 5.1 | NR |
Pelzer et al[37], 2011 | OFF | 23 | 0% | NR | 4.8 | NR |
Pelzer et al[38], 2008 | OFF | 76 | NR | 3 | 6.1 | NR |
Assaf et al[40], 2011 | FOLFIRINOX | 27 | 19% | 5.4 | 8.5 | NR |
Togawa et al[88], 2007 | Cisplatin, S-1 | 17 | 29% | NR | 10 | 32% |
Kim et al[89], 2012 | Cisplatin, S-1 | 11 | 0% | 1.5 | 2.7 | NR |
Takahara et al[90], 2013 | Oxaliplatin, S-1 | 30 | 10% | 3.4 | 5.0 | NR |
Cantore et al[41], 2004 | Oxaliplatin, irinotecan | 30 | 10% | 4.1 | 5.9 | 23% |
Oh et al[42], 2010 | Oxaliplatin, irinotecan | 14 | 21% | 1.4 | 4.1 | 7.1% |
Reni et al[43], 2006 | Oxaliplatin, raltitrexed | 41 | 24% | 1.8 | 5.2 | 12% |
Mazzer et al[44], 2009 | Oxaliplatin, pemetrexed | 16 | 56% | 3.3 | NR | NR |
Non-platinum based regimens | ||||||
Yoo et al[30], 2009 | FOLFIRI | 31 | 0% | 1.9 | 3.9 | NR |
Gebbia et al[45], 2010 | FOLFIRI | 40 | 15% | 3.7 | 6.0 | 0% |
Cereda et al[91], 2010 | FOLFIRI or XELIRI | 34 | 0% | 2.0 | 4.2 | 5.6% |
Zaniboni et al[46], 2012 | FOLFIRI | 50 | 8% | 3.2 | 5.0 | NR |
Neuzillet et al[47], 2012 | FOLFIRI | 63 | 7.9% | 3.0 | 6.6 | NR |
Mizuno et al[28], 2013 | S-1, irinotecan | 60 | 18% | 3.6 | 6.9 | NR |
Blaya et al[49], 2007 | Capecitabine, docetaxel | 24 | 13% | NR | NR | NR |
Katopodis et al[50], 2011 | Capecitabine, docetaxel | 31 | 9.7% | 2.4 | 6.4 | 15% |
Kim et al[51], 2009 | 5-FU, paclitaxel | 28 | 10% | 2.5 | 7.6 | NR |
Lee et al[92], 2009 | Conti-FAM3 | 31 | 12% | 2.3 | 6.7 | NR |
Shi et al[93], 2012 | Capecitabine, thalidomide | 31 | 6.5% | 2.7 | 6.1 | NR |
Saif et al[94], 2009 | Capecitabine, PHY906 | 25 | 5.3% | NR | NR | NR |
Ulrich-Pur et al[48], 2003 | Irinotecan, raltitrexed | 19 | 16% | 4.0 | 6.5 | NR |
Reni et al[95], 2004 | MDI | 15 | 0% | 1.7 | 6.1 | 0% |
Cereda et al[96], 2011 | Mitomycin, ifosfamide | 21 | 4.8% | 1.7 | 3.7 | 9.5% |
Ko et al[52], 2008 | Irinotecan, docetaxel | 14 | 0% | 1.2 | 4.5 | 21% |
- Citation: Walker EJ, Ko AH. Beyond first-line chemotherapy for advanced pancreatic cancer: An expanding array of therapeutic options? World J Gastroenterol 2014; 20(9): 2224-2236
- URL: https://www.wjgnet.com/1007-9327/full/v20/i9/2224.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i9.2224